Does the media favor GENB or RYTM?

In the previous week, Rhythm Pharmaceuticals had 6 more articles in the media than Generate Biomedicines. MarketBeat recorded 8 mentions for Rhythm Pharmaceuticals and 2 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of 1.87 beat Rhythm Pharmaceuticals' score of 0.79 indicating that Generate Biomedicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Generate Biomedicines 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Rhythm Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MIRM or GENB?

In the previous week, Mirum Pharmaceuticals had 2 more articles in the media than Generate Biomedicines. MarketBeat recorded 4 mentions for Mirum Pharmaceuticals and 2 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of 1.87 beat Mirum Pharmaceuticals' score of 0.88 indicating that Generate Biomedicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Generate Biomedicines 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to GENB or LNTH?

In the previous week, Lantheus had 2 more articles in the media than Generate Biomedicines. MarketBeat recorded 4 mentions for Lantheus and 2 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of 1.87 beat Lantheus' score of 1.35 indicating that Generate Biomedicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Generate Biomedicines 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Lantheus 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GENB or COGT more profitable?

Generate Biomedicines' return on equity of 0.00% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Generate Biomedicines N/A N/A N/A Cogent Biosciences N/A -104.27% -54.64%

Does the media refer more to GENB or COGT?

In the previous week, Cogent Biosciences had 2 more articles in the media than Generate Biomedicines. MarketBeat recorded 4 mentions for Cogent Biosciences and 2 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of 1.87 beat Cogent Biosciences' score of 1.71 indicating that Generate Biomedicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Generate Biomedicines 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cogent Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to GENB or PTCT?

In the previous week, PTC Therapeutics had 11 more articles in the media than Generate Biomedicines. MarketBeat recorded 13 mentions for PTC Therapeutics and 2 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of 1.87 beat PTC Therapeutics' score of 0.60 indicating that Generate Biomedicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Generate Biomedicines 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive PTC Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Generate Biomedicines (GENB) Competitors

$13.40 -0.43 (-3.11%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$13.53 +0.13 (+0.95%)

As of 07/24/2026 07:34 PM Eastern

Compare

GENB vs. RYTM, MIRM, LNTH, COGT, and PTCT

Should you buy Generate Biomedicines stock or one of its competitors? MarketBeat compares Generate Biomedicines with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Generate Biomedicines include Rhythm Pharmaceuticals (RYTM), Mirum Pharmaceuticals (MIRM), Lantheus (LNTH), Cogent Biosciences (COGT), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical products" industry.

How does Generate Biomedicines compare to Rhythm Pharmaceuticals?

Generate Biomedicines (NASDAQ:GENB) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Generate Biomedicines has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Generate Biomedicines' return on equity of 0.00% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

Generate Biomedicines has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Generate Biomedicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$30.30M	56.69	-$137.17M	-$1.07	N/A
Rhythm Pharmaceuticals	$189.76M	36.87	-$196.54M	-$3.13	N/A

Generate Biomedicines currently has a consensus target price of $25.40, indicating a potential upside of 89.55%. Rhythm Pharmaceuticals has a consensus target price of $138.29, indicating a potential upside of 35.44%. Given Generate Biomedicines' stronger consensus rating and higher possible upside, analysts plainly believe Generate Biomedicines is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

In the previous week, Rhythm Pharmaceuticals had 6 more articles in the media than Generate Biomedicines. MarketBeat recorded 8 mentions for Rhythm Pharmaceuticals and 2 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of 1.87 beat Rhythm Pharmaceuticals' score of 0.79 indicating that Generate Biomedicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Rhythm Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Generate Biomedicines beats Rhythm Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Generate Biomedicines compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Generate Biomedicines (NASDAQ:GENB) are both pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

Generate Biomedicines has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Generate Biomedicines' return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Generate Biomedicines	N/A	N/A	N/A

Mirum Pharmaceuticals has higher revenue and earnings than Generate Biomedicines. Generate Biomedicines is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$569.61M	12.10	-$23.36M	-$13.61	N/A
Generate Biomedicines	$30.30M	56.69	-$137.17M	-$1.07	N/A

In the previous week, Mirum Pharmaceuticals had 2 more articles in the media than Generate Biomedicines. MarketBeat recorded 4 mentions for Mirum Pharmaceuticals and 2 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of 1.87 beat Mirum Pharmaceuticals' score of 0.88 indicating that Generate Biomedicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Generate Biomedicines	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Mirum Pharmaceuticals presently has a consensus target price of $143.40, suggesting a potential upside of 26.87%. Generate Biomedicines has a consensus target price of $25.40, suggesting a potential upside of 89.55%. Given Generate Biomedicines' higher possible upside, analysts plainly believe Generate Biomedicines is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Summary

Mirum Pharmaceuticals and Generate Biomedicines tied by winning 7 of the 14 factors compared between the two stocks.

How does Generate Biomedicines compare to Lantheus?

Generate Biomedicines (NASDAQ:GENB) and Lantheus (NASDAQ:LNTH) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

99.1% of Lantheus shares are held by institutional investors. 1.7% of Lantheus shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Lantheus has higher revenue and earnings than Generate Biomedicines. Generate Biomedicines is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$30.30M	56.69	-$137.17M	-$1.07	N/A
Lantheus	$1.54B	4.43	$233.56M	$4.15	25.26

In the previous week, Lantheus had 2 more articles in the media than Generate Biomedicines. MarketBeat recorded 4 mentions for Lantheus and 2 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of 1.87 beat Lantheus' score of 1.35 indicating that Generate Biomedicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Lantheus	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Generate Biomedicines presently has a consensus price target of $25.40, indicating a potential upside of 89.55%. Lantheus has a consensus price target of $110.43, indicating a potential upside of 5.35%. Given Generate Biomedicines' stronger consensus rating and higher probable upside, equities research analysts clearly believe Generate Biomedicines is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Lantheus has a net margin of 18.05% compared to Generate Biomedicines' net margin of 0.00%. Lantheus' return on equity of 29.32% beat Generate Biomedicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
Lantheus	18.05%	29.32%	15.00%

Summary

Lantheus beats Generate Biomedicines on 11 of the 15 factors compared between the two stocks.

How does Generate Biomedicines compare to Cogent Biosciences?

Generate Biomedicines (NASDAQ:GENB) and Cogent Biosciences (NASDAQ:COGT) are both pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

Generate Biomedicines' return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
Cogent Biosciences	N/A	-104.27%	-54.64%

Generate Biomedicines currently has a consensus price target of $25.40, suggesting a potential upside of 89.55%. Cogent Biosciences has a consensus price target of $45.90, suggesting a potential upside of 15.44%. Given Generate Biomedicines' stronger consensus rating and higher possible upside, analysts plainly believe Generate Biomedicines is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85

In the previous week, Cogent Biosciences had 2 more articles in the media than Generate Biomedicines. MarketBeat recorded 4 mentions for Cogent Biosciences and 2 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of 1.87 beat Cogent Biosciences' score of 1.71 indicating that Generate Biomedicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cogent Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Generate Biomedicines has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Generate Biomedicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$30.30M	56.69	-$137.17M	-$1.07	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

Summary

Generate Biomedicines beats Cogent Biosciences on 9 of the 12 factors compared between the two stocks.

How does Generate Biomedicines compare to PTC Therapeutics?

Generate Biomedicines (NASDAQ:GENB) and PTC Therapeutics (NASDAQ:PTCT) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

Generate Biomedicines has a net margin of 0.00% compared to PTC Therapeutics' net margin of -22.58%. Generate Biomedicines' return on equity of 0.00% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
PTC Therapeutics	-22.58%	-362.45%	-6.76%

PTC Therapeutics has higher revenue and earnings than Generate Biomedicines. PTC Therapeutics is trading at a lower price-to-earnings ratio than Generate Biomedicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$30.30M	56.69	-$137.17M	-$1.07	N/A
PTC Therapeutics	$1.73B	3.68	$682.64M	-$2.33	N/A

In the previous week, PTC Therapeutics had 11 more articles in the media than Generate Biomedicines. MarketBeat recorded 13 mentions for PTC Therapeutics and 2 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of 1.87 beat PTC Therapeutics' score of 0.60 indicating that Generate Biomedicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
PTC Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Generate Biomedicines presently has a consensus target price of $25.40, suggesting a potential upside of 89.55%. PTC Therapeutics has a consensus target price of $92.29, suggesting a potential upside of 20.13%. Given Generate Biomedicines' stronger consensus rating and higher possible upside, research analysts plainly believe Generate Biomedicines is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.80

Summary

Generate Biomedicines beats PTC Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Generate Biomedicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GENB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GENB vs. The Competition

Export

Metric	Generate Biomedicines	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$1.72B	$3.11B	$7.24B	$12.25B
Dividend Yield	N/A	15.21%	40.99%	9.79%
P/E Ratio	-12.52	13.16	23.62	23.71
Price / Sales	56.69	2,720.84	160.98	74.42
Price / Cash	N/A	25.90	165.01	59.64
Price / Book	N/A	9.39	12.77	6.07
Net Income	-$137.17M	-$34.07M	$120.21M	$331.99M
7 Day Performance	-1.18%	0.45%	-0.95%	-0.61%
1 Month Performance	-18.39%	0.10%	-1.98%	-1.98%
1 Year Performance	N/A	9.87%	9.82%	13.67%

Generate Biomedicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GENB Generate Biomedicines	2.7437 of 5 stars	$13.40 -3.1%	$25.40 +89.6%	N/A	$1.72B	$30.30M	N/A	312	News Coverage Positive News Analyst Upgrade
RYTM Rhythm Pharmaceuticals	2.9798 of 5 stars	$105.81 +1.2%	$138.29 +30.7%	+17.0%	$7.26B	$189.76M	N/A	140
MIRM Mirum Pharmaceuticals	2.8946 of 5 stars	$117.52 +0.8%	$143.40 +22.0%	+116.7%	$7.16B	$521.31M	N/A	140	Upcoming Earnings
LNTH Lantheus	3.3187 of 5 stars	$106.81 +2.3%	$110.43 +3.4%	+47.8%	$6.94B	$1.55B	25.69	1,193	News Coverage
COGT Cogent Biosciences	1.7986 of 5 stars	$39.45 +3.0%	$45.90 +16.3%	+226.2%	$6.74B	N/A	N/A	80	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GENB) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Generate Biomedicines (GENB) Competitors

GENB vs. RYTM, MIRM, LNTH, COGT, and PTCT

How does Generate Biomedicines compare to Rhythm Pharmaceuticals?

Summary

How does Generate Biomedicines compare to Mirum Pharmaceuticals?

Summary

How does Generate Biomedicines compare to Lantheus?

Summary

How does Generate Biomedicines compare to Cogent Biosciences?

Summary

How does Generate Biomedicines compare to PTC Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GENB vs. The Competition

Generate Biomedicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Generate Biomedicines (GENB) Competitors

GENB vs. RYTM, MIRM, LNTH, COGT, and PTCT

How does Generate Biomedicines compare to Rhythm Pharmaceuticals?

Is GENB or RYTM more profitable?

Which has stronger earnings and valuation, GENB or RYTM?

Do analysts recommend GENB or RYTM?

Does the media favor GENB or RYTM?

Summary

How does Generate Biomedicines compare to Mirum Pharmaceuticals?

Is MIRM or GENB more profitable?

Which has stronger valuation and earnings, MIRM or GENB?

Does the media refer more to MIRM or GENB?

Do analysts prefer MIRM or GENB?

Summary

How does Generate Biomedicines compare to Lantheus?

Do insiders and institutionals have more ownership in GENB or LNTH?

Which has stronger valuation & earnings, GENB or LNTH?

Does the media refer more to GENB or LNTH?

Do analysts recommend GENB or LNTH?

Is GENB or LNTH more profitable?

Summary

How does Generate Biomedicines compare to Cogent Biosciences?

Is GENB or COGT more profitable?

Do analysts prefer GENB or COGT?

Does the media refer more to GENB or COGT?

Which has higher valuation and earnings, GENB or COGT?

Summary

How does Generate Biomedicines compare to PTC Therapeutics?

Is GENB or PTCT more profitable?

Which has preferable valuation and earnings, GENB or PTCT?

Does the media refer more to GENB or PTCT?

Do analysts rate GENB or PTCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GENB vs. The Competition

Generate Biomedicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools